Researchers evaluate minimal residual disease status in 128 adults with relapsed or refractory follicular lymphoma treated with epcoritamab.

A team led by researchers at Weill Cornell Medicine has identified important drivers of the transformation of a type of blood cancer called follicular lymphoma from a slow-growing form to the ...

AbbVie ABBV announced that the European Commission (EC) approved the expanded use of Tepkinly (epcoritamab) for the relapsed ...

Researchers at University of Tsukuba have identified multiple T-cell subtypes with unique characteristics in follicular lymphoma, a prevalent type of blood cancer. These T cells regulate the ...

The decision is based on data from the pivotal Phase III EPCORE FL-1 trial.

A team led by researchers at Weill Cornell Medicine has identified important drivers of the transformation of a type of blood cancer called follicular lymphoma from a slow-growing form to the ...

Reflecting on data presented at ASH 2025, Dr Kami Maddocks notes that several findings may change practice, including approval of epcoritamab combined with rituximab and lenalidomide (R2) for ...

Sponsored advertising content is provided by Genmab A/S and AbbVie and does not necessarily reflect the views of CURE Each person’s experience with follicular lymphoma (FL) is unique. Whether you’re ...

The shift toward dual-targeting bispecifics and the imminent arrival of highly efficacious triple combinations could shift the follicular lymphoma treatment space. The future treatment landscape for ...

Five years ago, I finished treatment and was determined to be no evidence of disease. Until my most recent CT scan, there’s been no sign of recurrence. Yesterday, I saw my oncologist and he reviewed ...

Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) has reported the first complete response in the concurrent Bruton Tyrosine Kinase inhibitor (BTKi) cohort of its ongoing Phase 1b azer-cel trial, marking an ...

Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is a standard treatment for relapsed or refractory B-cell non-Hodgkin lymphomas. Long-term results and curative potential remain uncertain. We ...